OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)

NCT01916785 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

289

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelogenous Leukemia, BCR/ABL Positive

Interventions

DRUG: Dasatinib

Sponsor

Versailles Hospital

Collaborators

[object Object]
[object Object]